Professional Hospital Furnishers
Thank you for Visiting Us at MEDICA 2003 - Download catalogues in PDF format - Order now & avail 10 / 20% discount - Liposuction Canulas for Cosmetic Surgery now in production


  PRODUCT CATALOGUE
  find the required instrument...

 

type in the name of instrument & click GO 
  optional search by...

alphabet.gif

  Order Catalogues
  Free Downloads
   MEMBERS
























   Contact Us
   Product Range
   Accreditations
   Production Operations
   Future Plans
   Testimonials...




Articles back

How to Test Drugs on Kids? FDA Starts the Debate

Little Information Is Available on Medications' Effects on Children
In March 1958, researchers at the University of Southern California in Los Angeles began a study to determine the effects of the antibiotic chloramphenicol on premature infants. By February 1959, over 60% of the babies who had been given the drug were dead. In total, 52 of the 126 children enrolled in the study eventually died. But the researchers never halted the study, despite knowing that chloramphenicol could kill.
"We discussed stopping the study early, and the decision was made ... that unless you have convincing evidence, nobody's going to believe you," one of the researchers said later. The study's goal was to discredit the use of that antibiotic in infants -- a practice that may have resulted in thousands of more deaths, the researchers said in their defense.
Now, more than 30 years later, U.S. health officials once again want convincing evidence about drugs' effects on children. To make it happen, the FDA has passed a rule requiring drug makers to conduct clinical trials aimed at determining the effectiveness and effects of commonly used medications on children, beginning this December.
There is a surprising lack of information about the appropriate use of prescription drugs in children, the FDA says. The agency estimates that more than half of the drugs approved every year that are likely to be used in children are neither adequately tested nor labeled for children, leaving doctors to determine the appropriate doses. Information on drug safety and effectiveness is especially sparse for children under age 2.
But in an effort to avoid past mistakes, FDA officials this time are consulting experts on how to establish the guidelines for these types of studies. Those consultations began this week with a number of meetings between FDA officials, pediatric specialists, and experts in other medical specialties such as oncology. The issue at the heart of the discussions: To what level of risk or discomfort can a child be ethically exposed to in a clinical trial?
Dianne Murphy, MD, associate director of pediatrics at the FDA, says the agency believes that these trials should be conducted using only people who may benefit. But whether the studies ethically can include a placebo group largely remains a point of contention, she says.
A placebo generally is a sugar pill or other facsimile of the real drug being studied used for comparison purposes. It has no treatment benefit. While some scientists and the FDA believe that side effects and clinical benefits of a drug cannot be determined without the use of a group taking only a placebo, others argue that it is unethical to leave children untreated -- even when the child suffers from a nonfatal disease, such as a skin rash.
"An investigator's chief concern ought to be the health and well-being of her patients," Charles Weijer, MD, cautioned FDA officials at the meeting, which included several representatives from Europe who are working on developing international standards. The standards set by the FDA also will set a precedent for what happens abroad, cautioned Weijer, a bioethics and an assistant professor of medicine at Dalhousie University in Nova Scotia.
Still, there are several areas in which researchers agree, says Robert Temple, MD, director of medical policy at the FDA's Center for Drug Evaluation and Research. Overall, they agree that placebos may be used when there is no alternative therapy. They also agree that neither children nor adults should be denied treatment if they are suffering from a life-threatening disease.
As for nonfatal diseases, using alternative study designs could help bridge the opinion gap among researchers, Temple says. Among those is a simple method that would test the standard treatment vs. the standard treatment plus the new drug -- in effect making the group getting the standard treatment act as the placebo group.
But while this type of study could help test certain drugs in fields such as oncology, or cancer, it is unlikely to help researchers looking at disorders for which there is no standard treatment regimen, such as depression, Temple says. In those areas, the most effective studies would test the drug in question against a placebo, while allowing patients to withdraw if they exhibit serious symptoms.
The debate over placebos is not the only issue the FDA faces in its quest to involve children in clinical trials, Murphy says. For example, the FDA must determine how to design the informed consent form, a form designed to ensure that study participants understand the risks.
Ironically, when members of Congress grilled the University of Southern California researchers in 1972 about the chloramphenicol experiment, they at first criticized the researchers for withholding needed drugs by including a placebo group, Murphy says. It was not until someone observed that most of the deaths were among babies in the group receiving treatment that the researchers were criticized for administering the antibiotic.
All of this leaves the FDA with a lot of ground to cover in a short time. FDA officials themselves have requested 332 studies involving children, of which they estimate about 282 will be conducted. Thanks to financial incentives passed by Congress in 1997, such as granting six additional months of marketing exclusivity rights for drug makers who conduct voluntary studies of their products on children, the number of studies initiated by someone other than the FDA has exploded over the past few years.
But for the FDA, that is good news, Murphy says. While some may believe that the USC experiment was unfounded, the principle that guided those researchers 40 years ago still applies today, she says. "Unless you have convincing evidence, nobody's going to believe you."

back

 

home.gif help.gif email.gif

 subscribe to newsletter
 

go.gif 

Download Now



bnr_right02.gif

bnr_right03.gif
 


DESIGNED & POWERED BY
SOLINCS

copyright 2002 - professional hospital furnishers